Postpartum Depression Drugs Market Size, Share & Trends Analysis Report By Type (Postpartum Blues, Anxiety, PTSD), Treatment (Pharmacotherapy, Hormonal Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 -

Postpartum Depression Drugs Market Size, Share & Trends Analysis Report By Type (Postpartum Blues, Anxiety, PTSD), Treatment (Pharmacotherapy, Hormonal Therapy), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Postpartum Depression Drugs Market Growth & Trends

The global postpartum depression drugs market is anticipated to reach USD 1.59 billion by 2030 and is expected to expand at a CAGR of 9.63% during the forecast period, according to a new report by Grand View Research, Inc. The increasing number of pregnancies worldwide primarily drives market growth. Many women suffer from postpartum depression (PPD) after having a baby and are at high risk of developing major depression later in life. According to the Cleveland Clinic Estimate, postpartum depression is a common condition that affects 1 in 7 women after giving birth to a child. Thus, rising government support for women who had childbirth and are suffering from mood disorders like PDD is expected to boost demand for drugs over the forecast period.

According to the Indian Association of Preventive & Social Medicine, every year, around 30 million women experience pregnancy, and 27 million women have live childbirths. In July 2022, the Government of India launched several schemes to support pregnant women, such as Janani Suraksha Yojana (JSY) and Janani Shishu Suraksha Karyakaram (JSSK). Under these programs, the government offers free of cost treatment related to pregnancy, such as diagnostics, medicines, and other consumables. Thus, initiatives like JSSK and JSY support women in completing treatment such as postpartum depression, simultaneously driving market growth during the forecast period.

Another significant factor driving the adoption of postpartum depression drugs is rising healthcare expenditures, which help to improve infrastructure and improve patient access to healthcare facilities. According to the PETERSON-KFF Health System Tracker report, women spend around USD 18,865 annually on pregnancy, childbirth, and postpartum treatment. There is significant variation. around this, spending and costs vary significantly by region worldwide. The increasing access of women to PPD drug treatment is anticipated to drive market growth in the coming years.

Postpartum Depression Drugs Market Report Highlights

• The postpartum anxiety segment held the largest share of the market in 2023. This can be attributed to the disease's high treatment rate and growing prevalence in developed and developing countries.
• Based on the treatment type, the hormonal therapy segment is expected to grow at the fastest CAGR during the forecast period.This can be attributed to the development and commercialization of new hormonal drugs and increased adoption by smaller hospitals and facilities for the treatment of PDD.
• In 2023, the oral segment held the largest share of the market based on the route of administration. This dominance can be attributed to the increase in the prevalence and incidence of disease worldwide, the large availability of products, and the rising demand for new generic oral drugs for treatment.
• The hospital pharmacy segment held the largest share of the market based on distribution channels in 2023. Hospital treatment rates, patient preference for hospitals over other healthcare settings for PDD treatment, and the increasing number of patients visiting hospitals.
• North America dominated the market owing to factors such as advanced healthcare infrastructure, rising disease prevalence, and favorable regulatory environment.

Please note The report will be delivered in 2-3 business days upon order notification.